Lynn G Feun MD

Oncology•Miami, FL

Professor, Medicine, University of Miami School of Medicine

Join to View Full Profile

1475 NW 12th AveMiami, FL 33136
Phone+1 305-243-6606
Fax+1 305-243-5239

Summary

Dr. Lynn Feun is medical oncology specialist based in Miami, FL, with a focus on melanoma and cutaneous malignancies, liver cancer. He completed his fellowship in Hematology and Medical Oncology at Detroit Medical Center/Wayne State University and residency in Internal Medicine at Wayne State University School of Medicine. Dr. Feun has published research on melanoma, skin cancers, liver cancer including its diagnosis and management, and participates in clinical trials related to advanced hepatocellular carcinoma and melanoma. He has received the CMS Meaningful Use Stage 1 Certification and has been recognized as a Super Doctor by SuperDoctors.com.

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1977 - 1979
Wayne State University School of MedicineResidency, Internal Medicine, 1976 - 1977
Wayne State University School of MedicineClass of 1974

Certifications & Licensure

FL State Medical License 1986 - 2027
MI State Medical License 1979 - 2026
TX State Medical License 1979 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

S9624 Ifosfamide in Treating Patients With Meningeal Tumors Start of enrollment: 1998 Jul 01
Terminated
Phase 2
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma Start of enrollment: 2012 Jul 01
Completed
Phase 2
Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma Start of enrollment: 2013 Aug 21
Completed
Phase 1
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 12
COMPLETED
PHASE3
Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors Start of enrollment: 2011 Jun 08
Completed
Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma Start of enrollment: 2016 May 06
Completed
Phase 2
AFPᶜ³³²T in Advanced HCC Start of enrollment: 2017 May 08
ACTIVE_NOT_RECRUITING
PHASE1
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Start of enrollment: 2023 Jan 19
TERMINATED
PHASE2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Correction: Shoushtari et al. A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma.2021,, 5504.
Alexander N Shoushtari, Shaheer Khan, Kimberly Komatsubara, Lynn Feun, Nicolas Acquavella
Cancers. 2025-09-16
1 citations
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma.
Tim Meyer, Richard S Finn, Mitesh Borad, Amit Mahipal, Julien Edeline
Journal of Hepatology. 2025-08-12
1 citations
Looking Toward the Future: Emerging Therapies for Hepatocellular Carcinoma.
Sanjana Rao, Sean-Patrick Prince, Sirisha Gaddipati, Lynn Feun, Nkiruka Ezenwajiaku
Gastroenterology & Hepatology. 2025-05-01

Lectures

Plasma biomarkers to predict pembrolizumab response in HCC patients.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Press Mentions

The Noble Calling of Medicine: Q and a with Dr. Lynn FeunOctober 27th, 2025

Grant Support

Arginine Deprivation: A Targeted Therapy For MelanomaNational Cancer Institute2004–2006
New Therapeutic Approaches For Malignant GliomaNational Cancer Institute1993–1995

Professional Memberships

American Society of Clinical Oncology - ASCO
Member